HOME 
News News by industry Life Sciences New Astex data reveals tumour shrinkage in advanced cancers
News News by industry Life Sciences New Astex data reveals tumour shrinkage in advanced cancers | New Astex data reveals tumour shrinkage in advanced cancers |
| Written by Alice Walker | |
| Wednesday, 28 May 2008 | |
 Astex drug discovery technology is producing encouraging cancer breakthroughs Both of these candidates were discovered internally at Astex using its industry-leading fragment-based drug discovery platform, Pyramid™. During the meeting Astex’s investigators will present the first clinical data from an international dose escalation study of AT7519, a potent cell cycle inhibitor. The results of this study demonstrate evidence of tumour shrinkage and biological activity in patients with advanced cancer treated with AT7519. In addition, Astex’s investigators will make two presentations on AT9283, a multi-targeted kinase inhibitor. One will be the initial release of information from an ongoing Phase I dose escalation study in patients with refractory solid tumours. This study reveals evidence of significant disease stabilisation in a proportion of patients. The other will provide an update on the ongoing Phase I/II trial of AT9283 in patients with refractory leukaemia where early clinical activity has been reported. Astex has a further five internal drug discovery programmes and is pursuing an additional five projects in partnership with leading pharmaceutical companies including Novartis, AstraZeneca and Boehringer Ingelheim.
Set as favorite
Bookmark
Email This
Hits: 638 Trackback(0)
Comments (0)
 Write comment
This content has been locked. You can no longer post any comment.
|
TrackBack URI for this entry
Subscribe to this comment's feed
Show/Hide comments
Show/Hide comment form
Delicious
Digg
NewsVine
Reddit
Technorati| < Prev | Next > |
|---|
|
Featured business directory listing
 The Royal Bank of Scotland Group - East of England www.rbs.co.uk Category: Banks and Financial |
Site Login
 |